<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Barts Cancer Institute</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7CC8739C-8587-496A-8602-F18B55FFCD97"><gtr:id>7CC8739C-8587-496A-8602-F18B55FFCD97</gtr:id><gtr:firstName>Melissa</gtr:firstName><gtr:surname>Phillips</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1001993"><gtr:id>07FB4FA2-874D-4230-B5E4-15BD30ADF611</gtr:id><gtr:title>The effect of tumour microenvironment on arginine deprivation in malignant pleural mesothelioma.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1001993</gtr:grantReference><gtr:abstractText>Mesothelioma is increasing in the UK and many other countries worldwide, and novel approaches are urgently required. New targeted therapies require an understanding of mesothelioma biology and would complement established treatments such as surgery, chemotherapy and radiotherapy. Previously, we have shown that mesothelioma cancer cells die when they are starved of arginine. This amino acid nutrient is an important building block of proteins and other key molecules vital to the growth of certain cancer cells, such as mesothelioma. Based on our research, a national clinical trial of the arginine-lowering agent, ADI-PEG20, is due to start in the autumn of 2010 in patients with mesothelioma. Although, arginine starvation may be a promising therapy in some cancers, we are concerned that a type of cell, known as the macrophage, within the cancer, can directly feed the tumour cells with arginine, reducing the effectiveness of arginine-lowering drugs. Thus, we wish to study the macrophage-mesothelioma cell relationship in the context of ADI-PEG20. We believe that this project will be key to the development of novel strategies for the treatment of mesothelioma, and potentially improve the outlook of patients with this devastating disease.</gtr:abstractText><gtr:technicalSummary>Aims: (a) To determine whether the macrophage component of the tumour microenvironment is a critical modulator of the response of malignant mesothelioma to arginine-depleting agents; and b) to develop strategies that overcome MPM stromal resistance to arginine deprivation.

Background: Tumours deficient in argininosuccinate synthetase (ASS1), a key enzyme involved in arginine synthesis, are auxtrophic for arginine and sensitive to amino acid deprivation. However, arginine derived from the tumour microenvironment, particularly tumour-associated macrophages (TAMs), may limit the clinical effectiveness of arginine-catabolising enzymes, such as pegylated arginine deiminase (ADI-PEG20) in the treatment of ASS1-negative tumours. Previously, we have shown that malignant mesothelioma (MPM) cells undergo caspase-dependent apoptosis with ADI-PEG20 treatment. Since MPM is an ASS1-methylated and macrophage-rich tumour, it provides an excellent model to study whether the tumour microenvironment regulates the response in ASS1-negative cancers to arginine deprivation. 

Objectives: First, I will validate the host lab?s preliminary Affymetrix gene expression data, which reveals widespread regulation of immune and inflammatory pathways in ADI-PEG20-treated MPM cell lines, including TGF- 2, FGFB1, IL-1 , IL-6, IL-8, IL-11, IL-24, CXCL2, CXCL3, and VEGF-A. Second, I will analyse the effect of arginine deprivation on the MPM-TAM interaction in vitro and in vivo. Third, I will determine the effect of arginine deprivation on the tumour microenvironment using samples from a multicentre clinical trial of ADI-PEG20 in patients with MPM (ADAM Trial).

Design and methodology: The project explores basic mechanisms of TAM-tumour cell interactions and is fully integrated into the ADAM clinical trial. I will employ a range of cell and molecular biology techniques all of which are established in the host or in collaborating labs: the micro fluidic card platform to validate the Affymetrix da with subsequent gene pathway interrogation using in situ hybridisation of MPM tumour sections; co-culture experiments of TAMs and MPM cells using small molecule inhibitors and/or blocking antibodies to determine whether TAM-mediated ADI-PEG20 resistance is reversible; and animal studies aimed at either depleting or re-educating TAMs, using liposome-encapsulated clodronate or small molecules/antibodies respectively, to validate that TAMs are a critical modulator of the response of ASS1-negative MPM to arginine deprivation in vivo.

Scientific and Medical Opportunities: Rigorous training will be provided in the scientific method at the Barts Cancer Research UK Centres for Molecular Oncology and Imaging, Cancer and Inflammation and Tumour Biology. In addition, my studentship will link into a weekly thoracic oncology clinic, providing an understanding of clinical trial design and translational clinical research.</gtr:technicalSummary><gtr:fund><gtr:end>2015-09-03</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-10-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>235748</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>talk to a patient advocate group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4E8A6A10-ED7D-4FAA-8D11-BE9FA6A402A5</gtr:id><gtr:impact>gave patient advocate group an update of current management and areas they can consider for further funraising / lobbying opportunities

the group was keen to hear more about how they can help improve oncology services</gtr:impact><gtr:outcomeId>545caa404175b9.90838873</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lung Cancer Forum for Nurse Specialists</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5539D664-5311-44A7-AF2F-BFF2947B110A</gtr:id><gtr:impact>This was an oral presentation I gave on trials in |mesothelioma specifically looking at the TRAP study in ASS1 negative tumours (related to my PhD). The audience were specialist lung cancer nurses at the National Lung Cancer Forum for Nurses</gtr:impact><gtr:outcomeId>56e1928b57b1a1.23295961</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AACR</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>571D79EB-533C-48AF-8F52-D3F3028A0158</gtr:id><gtr:impact>poster presentation of my research at AACR APril 2015 in Philadelphia USA</gtr:impact><gtr:outcomeId>56e19364c12897.43318473</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mecical  Oncology Teaching</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AB767E52-D57E-4315-8EC1-844B0828C008</gtr:id><gtr:impact>presentation on my research to medical oncology department at Barts Health</gtr:impact><gtr:outcomeId>56e19306cd1a89.06781738</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oral presentation at international conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E0391BCB-1387-4B13-9F63-AA480EBBDFD5</gtr:id><gtr:impact>planty of questions and constructive feedback following presentation with a few possible collaerations started

after the presentation, interested groups from the USA discussed collaberations</gtr:impact><gtr:outcomeId>545ca968d03c12.98727888</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C70E8898-76D0-428C-B036-68828055CD82</gtr:id><gtr:title>Tumour-Associated Macrophages</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef25d9912e931efe48097dffc335b4ef"><gtr:id>ef25d9912e931efe48097dffc335b4ef</gtr:id><gtr:otherNames>Phillips M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:isbn>978-1-4614-0661-7</gtr:isbn><gtr:outcomeId>SYvaLdzKGmc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F838DEC4-6194-4938-9670-A8473F355B3F</gtr:id><gtr:title>Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57aaaf68aab5e88079f0a409904ce38a"><gtr:id>57aaaf68aab5e88079f0a409904ce38a</gtr:id><gtr:otherNames>Szlosarek PW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>szaYWU2anzA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EE3C945-5929-4B78-A7FD-5B3161071D75</gtr:id><gtr:title>Randomized Trial of arginine deprivation with pegylated arginine deiminase in patients with malignant pleural mesothelioma</gtr:title><gtr:parentPublicationTitle>Lancet Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57aaaf68aab5e88079f0a409904ce38a"><gtr:id>57aaaf68aab5e88079f0a409904ce38a</gtr:id><gtr:otherNames>Szlosarek PW</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>56e195035805d7.24739116</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49E13A61-4237-4331-9D41-EE7C8A1DD172</gtr:id><gtr:title>Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges.</gtr:title><gtr:parentPublicationTitle>Cancer research and treatment : official journal of Korean Cancer Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b50ec7fefdf1dad6bb22e398b410778"><gtr:id>3b50ec7fefdf1dad6bb22e398b410778</gtr:id><gtr:otherNames>Phillips MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1598-2998</gtr:issn><gtr:outcomeId>MFRTU7PE8hZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11DC70AD-DCC5-43EC-951D-2E04FE1E6E5C</gtr:id><gtr:title>Macrophages mediate resistance to pegylated arginine deiminase in malignant pleural mesothelioma</gtr:title><gtr:parentPublicationTitle>International Mesothelioma Interest Group</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b50ec7fefdf1dad6bb22e398b410778"><gtr:id>3b50ec7fefdf1dad6bb22e398b410778</gtr:id><gtr:otherNames>Phillips MM</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>U7coPTBNJka</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001993</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>